MedTrace Logo

The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation

NCT06864052 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-03-07

No results posted yet for this study

Summary

This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through exploratory clinical trials.

Conditions

Interventions

DRUG

Administration of Apixaban

Apixaban 2.5mg BID or Apixaban 5mg BID

DRUG

Administration of Edoxaban

Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD

Sponsors & Collaborators

  • Ewha Womans University Seoul Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2029-09-30
Completion
2029-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06864052 on ClinicalTrials.gov